The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)